Scott+Scott Attorneys at Law LLP Again Alerts Investors of The Pending Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA)

A securities class action lawsuit has been filed against Iovance Biotherapeutics (IOVA) for allegedly making false and misleading statements regarding the commercial launch of its Amtagvi cancer treatment between May 9, 2024, and May 8, 2025. The lawsuit alleges Iovance failed to disclose longer timelines for new Authorized Treatment Centers and ineffectiveness in patient identification, leading to higher costs and lower revenue. The stock price fell 44.8% on May 9, 2025, after Iovance announced disappointing Q1 2025 revenue of $49.3 million and slashed its FY25 revenue guidance from $450-475 million to $250-300 million, citing issues with the Amtagvi launch.

Analysis

Iovance Biotherapeutics (NASDAQ: IOVA) is confronting a significant legal challenge in the form of a securities class action lawsuit filed in the Northern District of California. The lawsuit alleges that between May 9, 2024, and May 8, 2025, the company and its executives made materially false and misleading statements, or failed to disclose adverse facts, concerning the commercial launch of its flagship product, Amtagvi, a cell therapy for metastatic melanoma approved by the FDA on February 16, 2024. Specifically, the allegations point to undisclosed difficulties including longer-than-anticipated timelines for new Authorized Treatment Centers (ATCs) to begin administering Amtagvi, and ineffectiveness of the sales team and new ATCs in patient identification and selection, leading to higher patient drop-off rates. These issues purportedly resulted in increased costs and diminished revenue. The company's challenges became public on May 8, 2025, when it announced Q1 2025 total product revenue of $49.3 million, a substantial decrease from the $73.7 million reported in the prior quarter. Simultaneously, Iovance severely cut its full-year 2025 total product revenue guidance from an initial $450-475 million to a revised $250-300 million, citing "recent launch dynamics" and "experience with ATC growth trajectories and treatment timelines." The market reacted sharply to this news, with Iovance shares plummeting $1.42 per share, or 44.8%, to close at $1.75 on May 9, 2025, amidst unusually heavy trading volume, highlighting severe investor concern over the Amtagvi commercialization progress.

Key Decisions for Investors

• Investors should exercise extreme caution regarding Iovance Biotherapeutics, considering the significant operational headwinds impacting the Amtagvi launch, the drastic downward revision of FY25 revenue guidance, and the material risk posed by the ongoing securities class action lawsuit.
• Future performance will heavily depend on the company's ability to resolve the identified issues with Authorized Treatment Center efficiency and patient uptake; therefore, upcoming quarterly reports and management commentary on these specific operational metrics warrant close scrutiny.
• The revised FY25 revenue guidance of $250-$300 million establishes a new, lower baseline for performance expectations, and any failure to meet this lowered guidance could further erode investor confidence and negatively impact valuation.
• Shareholders who purchased or acquired Iovance securities between May 9, 2024, and May 8, 2025, and incurred losses, should investigate their eligibility to participate in the class action lawsuit and note the July 14, 2025 deadline to file a motion for lead plaintiff.